Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

Life Sciences

Volumn 80, Issue 10, 2007, Pages 979-988

  de Lago, Eva ^a   Ortega Gutiérrez, Silvia ^a   Ramos, José A ^a   López Rodríguez, Maria L ^a   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Endocannabinoid; Endocannabinoid uptake inhibition; Neurochemical effects; Neurotransmitters; UCM707

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; ENDOCANNABINOID; N (3 FURYLMETHYL)ARACHIDONAMIDE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN LEVEL; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; EXPERIMENTAL STUDY; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; LIMBIC CORTEX; MALE; METABOLITE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PUTAMEN; RAT; SEROTONIN BRAIN LEVEL; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; TEGMENTUM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ARACHIDONIC ACIDS; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ELECTROCHEMISTRY; ENDOCANNABINOIDS; FURANS; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; MALE; NOREPINEPHRINE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; SEROTONIN;

RATTUS;

EID: 33846616332     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.11.029     Document Type: Article

References (56)

1. Alexander J.P., and Cravatt B.F. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society 128 (2006) 9699-9704
2. Arévalo C., de Miguel R., and Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology, Biochemistry and Behavior 70 (2001) 123-131
3. 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacology, Biochemistry and Behavior 77 (2004) 675-684
4. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
5. Beltramo M., de Fonseca F.R., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., Sadile A.G., Giuffrida A., and Piomelli D. Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor. Journal of Neuroscience 20 (2000) 3401-3407
6. Bickford P.C., Shukitt-Hale B., and Joseph J. Effects of aging on cerebellar noradrenergic function and motor learning: nutritional interventions. Mechanism of Ageing and Development 111 (1999) 141-154
7. Blum K., Braverman E.R., Holder J.M., Lubar J.F., Monastra V.J., Miller D., Lubar J.O., Chen T.J., and Comings D.E. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of Psychoactive Drugs 32 (2000) 1-112
8. Comings D.E., and Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Progress in Brain Research 126 (2000) 325-341
9. de Lago E., Fernández-Ruiz J., Ortega-Gutiérrez S., Viso A., López-Rodríguez M.L., and Ramos J.A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. European Journal of Pharmacology 449 (2002) 99-103
10. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., and Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Research 1007 (2004) 152-159
11. de Lago E., Petrosino S., Valenti M., Morera E., Ortega-Gutiérrez S., Fernández-Ruiz J., and Di Marzo V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology 70 (2005) 446-452
12. de Lago E., Fernández-Ruiz J., Ortega-Gutiérrez S., Cabranes A., Pryce G., Baker D., López-Rodríguez M.L., and Ramos J.A. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. European Neuropsychopharmacology 16 (2006) 7-18
13. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., and Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters 483 (2000) 52-56
14. Etgen A.M., Ansonoff M.A., and Quesada A. Mechanisms of ovarian steroid regulation of norepinephrine receptor-mediated signal transduction in the hypothalamus: implications for female reproductive physiology. Hormones and Behavior 40 (2001) 169-177
15. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology 38 (1998) 179-200
16. Fernández-Ruiz J., and González S. Cannabinoid control of motor function at the basal ganglia. In: Pertwee R.G. (Ed). Handbook of Experimental Pharmacology - 168 - Cannabinoids (2005), Springer-Verlag, Heidelberg (Germany) 479-507
17. Fernández-Ruiz J., de Miguel R., Hernández M.L., Cebeira M., and Ramos J.A. Endocannabinoids and dopamine-related functions in the CNS. In: Onaivi E., Sugiura T., and Di Marzo V. (Eds). Endocannabinoids: The Brain and Body's Marijuana and Beyond (2006), CRC Press, Boca Raton, FL (USA) 261-290
18. Gingrich J.A., and Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl) 155 (2001) 1-10
19. Giuffrida A., Beltramo M., and Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Journal of Pharmacology and Experimental Therapeutics 298 (2001) 7-14
20. González S., Romero J., de Miguel R., Lastres-Becker I., Villanúa M.A., Makriyannis A., Ramos J.A., and Fernández-Ruiz J. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sciences 65 (1999) 327-336
21. Hoffman A.F., and Lupica C.R. Man-made marijuana: Endocannabinoid modulation of synaptic transmission and implications for the regulation of synaptic plasticity. In: Onaivi E., Sugiura T., and Di Marzo V. (Eds). Endocannabinoids: The Brain and Body's Marijuana and Beyond (2006), CRC Press, Boca Raton, FL (USA) 229-247
22. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine 9 (2003) 76-81
23. Khanolkar A.D., Abadji V., Lin S., Hill W.A., Taha G., Abouzid K., Meng Z., Fan P., and Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. Journal of Medicinal Chemistry 39 (1996) 4515-4519
24. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., Iacono A., Raso G.M., Meli R., Piomelli D., and Calignano A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404. Journal of Pharmacology and Experimental Therapeutics 317 (2006) 1365-1371
25. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S., Lastres-Becker I., González S., Fernández-Ruiz J., and Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. Journal of Medicinal Chemistry 44 (2001) 4505-4508
26. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S., Fowler C.J., Tiger G., de Lago E., Fernández-Ruiz J., and Ramos J.A. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. Journal of Medicinal Chemistry 46 (2003) 1512-1522
27. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S., Fowler C.J., Tiger G., de Lago E., Fernández-Ruiz J., and Ramos J.A. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. European Journal of Medicinal Chemistry 38 (2003) 403-412
28. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 (1951) 265-275
29. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology 308 (1996) 161-164
30. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., López-Rodríguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., and Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
31. McFarland M.J., and Barker E.L. Anandamide transport. Pharmacology and Therapeutics 104 (2004) 117-135
32. Moore S.A., Nomikos G.G., Dickason-Chesterfield A.K., Schober D.A., Schaus J.M., Ying B.P., Xu Y.C., Phebus L., Simmons R.M., Li D., Iyengar S., and Felder C.C. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proceedings of the National Academy of Sciences (USA) 102 (2005) 17852-17857
33. Morgane P.J., Galler J.R., and Mokler D.J. A review of systems and networks of the limbic forebrain/limbic midbrain. Progress in Neurobiology 75 (2005) 143-160
34. Moriello A.S., Balas L., Ligresti A., Cascio M.G., Durand T., Morera E., Ortar G., and Di Marzo V. Development of the first potential covalent inhibitors of anandamide cellular uptake. Journal of Medicinal Chemistry 49 (2006) 2320-2332
35. Murphy L.L., Muñoz R.M., Adrián B.A., and Villanúa M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiology of Disease 5 (1998) 432-446
36. Nicholson S.L., and Brotchie J.M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. European Journal of Neurology 9 (2002) 1-6
37. Ortar G., Ligresti A., De Petrocellis L., Morera E., and Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochemical Pharmacology 65 (2003) 1473-1481
38. Ortega-Gutierrez S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. Current Drug Targets. CNS and Neurological Disorders 4 (2005) 697-707
39. Ortega-Gutiérrez S., Molina-Holgado E., Arévalo-Martín A., Correa F., Viso A., López-Rodríguez M.L., Di Marzo V., and Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB Journal 19 (2005) 1338-1340
40. Osei-Hyiaman D., Harvey-White J., Batkai S., and Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. International Journal of Obesity (Lond) 30 (2006) S33-S38
41. Palkovits M., and Brownstein J. Maps and Guide to Microdissection of the Rat Brain (1988), Elsevier
42. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacology and Therapeutics 95 (2002) 165-174
43. Ramos E.J., Meguid M.M., Campos A.C., and Coelho J.C. Neuropeptide Y, alpha-melanocyte-stimulating hormone, and monoamines in food intake regulation. Nutrition 21 (2005) 269-279
44. Romero J., de Miguel R., García-Palomero E., Fernández-Ruiz J., and Ramos J.A. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Research 694 (1995) 223-232
45. Romero J., García-Palomero E., Fernández-Ruiz J., and Ramos J.A. Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behavioral Pharmacology 7 (1996) 299-302
46. Romero J., de Miguel R., Ramos J.A., and Fernández-Ruiz J. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sciences 62 (1998) 351-363
47. 9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn-Schmiedeberg's Archives of Pharmacology 372 (2006) 313-317
48. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends in Pharmacological Sciences 22 (2001) 565-572
49. Scholtissen B., Verhey F.R., Steinbusch H.W., and Leentjens A.F. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. Journal of Neural Transmission 113 (2006) 59-73
50. Smith S., and Sharp T. Measurement of GABA in rat brain microdialysates using o-phtaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 652 (1994) 228-233
51. Swanson C.J., and Schoepp D.D. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Annals of the New York Academy of Sciences 1003 (2003) 309-317
52. Thiébot M.H., Chaperon F., Fride E., and Onaivi E.S. Behavioral effects of endocannabinoids. In: Onaivi E., Sugiura T., and Di Marzo V. (Eds). Endocannabinoids: The Brain and Body's Marijuana and Beyond (2006), CRC Press, Boca Raton, FL (USA) 303-347
53. Tzavara E.T., Perry K.W., Rodríguez D.E., Bymaster F.P., and Nomikos G.G. The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. European Journal of Pharmacology 426 (2001) R3-R4
54. van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480 (2003) 133-150
55. Woodward D.J., Moises H.C., Waterhouse B.D., Yeh H.H., and Cheun J.E. The cerebellar norepinephrine system: inhibition, modulation, and gating. Progress in Brain Research 88 (1991) 331-341
56. Zygmunt P.M., Chuang H., Movahed P., Julius D., and Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. European Journal of Pharmacology 396 (2000) 39-42